Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts

Conditions: Melanoma (Skin), Pigmented Lesions

Sex: All

Enrollment: 4

Sponsor: Herlev Hospital

Location: Denmark

Summary

It has been suggested that pathologists' diagnostic accuracy and confidence could be improved if they gained access to additional clinical information and in-vivo clinical and dermoscopic images of melanocytic tumors. This study examines the effect of digital training for pathologists in interpreting dermoscopic and clinical skin tumor images. The primary outcome of the upcoming DAHT RCT (Dermoscopy Augmented Histology Trial, a randomized controlled trial) is the diagnostic value (accuracy, sensitivity, and specificity) for the intervention and control group. For this purpose, we need an irrefutable gold standard diagnosis for all DAHT cases. The DAHT consensus trial strives to establish this gold standard through a four-phased Delphi-like process.Aim: To establish a gold-standard diagnosis for all DAHT cases.Data collection of DAHT cases: Department of plastic surgery, Herlev hospital, year 2020-2021DAHT platform: Made in 2021-2023 by MelatechConsensus agreement: Four dermatopathologists assess all DAHT cases, year 2023

Eligibility Criteria

Inclusion Criteria:well-acknowledged expert in dermatopathologyInvited by our groupExclusion Criteria:Do not assess all DAHT cases

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05712551). StuddyBuddy aggregates publicly available trial information.